For years now, artificial intelligence has been hailed as both a savior and a destroyer. The technology really can make our lives easier, letting us summon our phones with a “Hey, Siri” and (more importantly) assisting doctors on the operating table. But as any science-fiction reader knows, AI is not an unmitigated good: It can be prone to the same racial biases as humans are, and, as is the case with self-driving cars, it can be forced to make murky split-second decisions that determine who lives and who dies. Like it or not, AI is only going to become an even more omnipresent force: We’re in a “watershed moment” for the technology, says Eric Schmidt, the former Google CEO.
A conversation with the former Google CEO Eric Schmidt.
Quantum physics is directly linked to consciousness: Observations not just change what is measured, they create it… Here’s the next episode of my new documentary Consciousness: Evolution of the Mind (2021), Part II: CONSCIOUSNESS & INFORMATION
The Lisa and Scott Stuart Center for Adolescent and Young Adult Cancers aims to address the unique challenges adolescent and young adult cancer patients face by expanding access to clinical trials for this patient group, offering planning and fertility services, and personalized medicine, according to a Sept. 27 news release.
New York City-based Memorial Sloan Kettering Cancer Center has created a new center dedicated to better serving the specific needs of young cancer patients.
Chipmakers are still catching up to demand following severe supply chain bottlenecks created by the pandemic. But manufacturing plants that were planned last year will likely start producing chips in the coming months, helping to alleviate shortages for PC parts and other microchips, Su said.
“We’ve always gone through cycles of ups and downs, where demand has exceeded supply, or vice versa,” Su said at the Code Conference in Beverly Hills, California. “This time, it’s different.”
The improvements will be gradual as more manufacturing capacity becomes available, Su said.
An inexpensive anti-seizure medication markedly improves learning and memory and other cognitive functions in Alzheimer’s patients who have epileptic activity in their brains, according to a study published in the Sept. 27th issue of JAMA Neurology.
“This is a drug that’s used for epilepsy,” says Keith Vossel, MD, MSc, director of the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA, and the principal investigator on the clinical trial. “We used it in this study for Alzheimer’s patients who had evidence of silent epileptic activity, which is seizure-like brain activity without the associated physical convulsions.”
Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Early symptoms include short-term memory loss, decline in problem solving, word-finding difficulties, and trouble with spatial navigation. Among Alzheimer’s patients, an estimated 10–22% develop seizures, while an additional 22–54% exhibit silent epileptic activity.
A large, UK-based study of genetics and autism spectrum disorder (ASD) has been suspended, following criticism that it failed to properly consult the autism community about the goals of the research. Concerns about the study include fears that its data could potentially be misused by other researchers seeking to ‘cure’ or eradicate ASD.
Study aimed at collecting DNA from 10,000 people with autism and their families has drawn criticism for failing to consult the autism community.
Dr. Jennifer Garrison, PhD (http://garrisonlab.com/) is Assistant Professor, Buck Institute for Research on Aging, Founder & Faculty Director, Global Consortium for Reproductive Longevity & Equality (https://www.buckinstitute.org/gcrle/), Assistant Professor in Residence, Cellular and Molecular Pharmacology, UCSF and Adjunct Assistant Professor of Gerontology, USC Leonard Davis School of Gerontology.
Dr. Garrison’s lab is interested in understanding how neuropeptides (a large class of signaling molecules which are secreted from neurons and transmit messages within the brain and across the nervous system) regulate changes in normal and aging animals as well in understanding how they control behavior at both the cell biological and neural circuit level.
Dr. Garrison received her PhD from the University of California San Francisco in Chemistry and Chemical Biology in the laboratory of Dr. Jack Taunton, where she discovered the molecular target of a natural product and elucidated a novel mechanism by which small molecules can regulate protein biogenesis. As a postdoctoral fellow in Dr. Cori Bargmann’s lab at the Rockefeller University, she showed that the nematode C. elegans produces a neuropeptide that is an evolutionary precursor of the mammalian peptides vasopressin and oxytocin, and mapped a neural circuit by which this molecule, nematocin, modulates mating behavior.
Dr. Garrison was named an Alfred P. Sloan Research Fellow and received a Glenn Foundation Award for Research in Biological Mechanisms of Aging in 2,014 and a Next Generation Leader at the Allen Institute for Brain Science in 2015. Her work is funded by the NIH National Institute of General Medical Sciences, the Glenn Foundation for Medical Research, the Alfred P. Sloan Foundation, and the Larry L. Hillblom Foundation.
Dr. Scott Gottlieb, the former FDA commissioner under President Trump, tells CNN’s Pamela Brown that the current Delta variant surge of coronavirus will likely finish running its course by the Thanksgiving holiday this fall.
